B of A Securities Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $307
Jazz Pharmaceuticals Public Limited Company
Jazz Pharmaceuticals Public Limited Company JAZZ | 0.00 |
B of A Securities analyst Jason Gerberry maintains Jazz Pharmaceuticals (NASDAQ:
JAZZ) with a Buy and raises the price target from $281 to $307.
